The FDA’s Pathway Forward For Cannabidiol (CBD): Understanding The Evolving U.S. Regulations (2025 Update)

Introduction: CBD’s Rise Meets Regulatory Complexity

Over the past decade, Cannabidiol (CBD) has rapidly transitioned from a niche compound to a mainstream ingredient across:

• Wellness products 
• Nutritional supplements 
• Cosmetics and personal care 
• Functional foods and beverages 

Despite its growing popularity and perceived therapeutic benefits, the regulatory landscape in the United States remains highly complex, restrictive, and evolving.

From a regulatory and scientific standpoint, CBD presents a unique challenge:

It exists at the intersection of pharmaceutical regulation, food safety, and consumer product compliance.

What is the FDA’s position on CBD in 2025?
The U.S. Food and Drug Administration states that cannabidiol (CBD) cannot currently be legally added to foods, beverages, or dietary supplements under the Federal Food, Drug, and Cosmetic Act, and is working with Congress to establish a new regulatory framework based on safety and scientific evidence.

Understanding Cannabidiol (CBD): Scientific and Regulatory Context

Cannabidiol is a non-psychoactive compound derived from cannabis plants, including hemp.

Key Characteristics

• Does not produce intoxicating effects 
• Widely studied for therapeutic applications 
• Used in prescription drugs, wellness products, and cosmetics 

Regulatory Complexity

CBD’s classification is complicated because:

• It is an active ingredient in approved drugs 
• It is also marketed in consumer products 
• Scientific data on long-term safety remains limited 

The Legal Foundation: FD&C Act Restrictions

Under the Federal Food, Drug, and Cosmetic Act:

• Ingredients approved or investigated as drugs cannot be added to food or dietary supplements unless specifically authorized 

Implications for CBD

Because CBD is an active ingredient in Epidiolex:

• It is prohibited in foods and dietary supplements 
• It requires regulatory approval for therapeutic use 

Insight

From a regulatory expertise perspective:

This restriction is designed to protect drug development integrity and ensure consumer safety

The 2018 Hemp Bill: A Turning Point but Not Full Legalization

The Agriculture Improvement Act of 2018 removed hemp from the Controlled Substances Act.

What Changed

• Hemp-derived CBD became legal at the federal level (≤0.3% THC) 

What Did NOT Change

• FDA retained authority over CBD-containing products 
• FD&C Act restrictions remained fully applicable 

Common Misconception

Many believe CBD could be freely used in food and supplements. However:

Declassification of hemp ≠ regulatory approval of CBD in consumer products

FDA’s Current Position on CBD Products

The U.S. Food and Drug Administration maintain a consistent stance:

CBD is NOT permitted in:

• Foods 
• Beverages 
• Dietary supplements 
• Animal feed 

FDA Enforcement Actions

The agency has issued multiple warning letters for:

• Unverified health claims 
• Mislabeling of CBD content 
• Unsafe or unapproved products 

Regulatory Objective

• Protect consumers 
• Preventing misleading claims 
• Ensure product safety 

Citizen Petitions and Industry Push for Regulation

Three major organizations submitted petitions requesting a regulatory pathway:

• Consumer Healthcare Products Association 
• Council for Responsible Nutrition 
• Natural Products Association 

FDA’s Decision (2023)

The FDA denied these petitions due to:

• Insufficient safety data 
• Lack of long-term exposure studies 
• Uncertainty around safe consumption levels 

Scientific Evidence and Data Reviewed by FDA

The FDA’s decision was based on comprehensive data analysis, including:

• Clinical data from Epidiolex 
• Peer-reviewed scientific studies 
• Internal FDA research 
• Public submissions 

Key Safety Concerns Identified by FDA

1. Liver Toxicity

• Elevated liver enzymes observed 
• Potential long-term damage 

2. Reproductive Health Risks

• Possible effects on male fertility 
• Limited reproductive safety data 

3. Vulnerable Populations

• Unknown risks for: 
  • Children 
  • Pregnant women 
  • Elderly populations 

4. Food Chain Risks

• CBD use in animal feed may impact: 
  • Meat 
  • Milk 
  • Eggs 

Insight

These concerns highlight a critical regulatory principle:

Widespread consumption requires well-defined safety thresholds

Why FDA Has Not Approved CBD Yet

The FDA requires:

• Defined safe daily intake levels 
• Comprehensive toxicology data 
• Long-term exposure studies 
• Standardized manufacturing practices 

Regulatory Gap

Currently, these elements are not sufficiently established, preventing approval.

The Future: A New Regulatory Pathway for CBD

Recognizing limitations of existing frameworks, the FDA is working with Congress to establish a new regulatory model.

Key Objectives of the New Framework

• Define safe consumption limits 
• Establish CBD-specific GMP standards 
• Implement labeling and marketing rules 
• Enable post-market surveillance systems 

Expected Impact

• Greater regulatory clarity 
• Safer product development 
• Structured market entry 

Compliance Challenges for Industry

Strategic Compliance Framework for CBD Companies

1. Regulatory Risk Assessment

• Evaluate product classification 
• Identify compliance gaps 

2. Safety & Toxicology Studies

• Conduct robust scientific research 
• Build evidence for regulatory approval 

3. Labeling & Claims Compliance

• Avoid therapeutic claims 
• Ensure accurate product information 

4. Global Regulatory Alignment

• Align with EU, Canada, and other markets 
• Prepare for future harmonization 

5. Documentation & Traceability

• Maintain audit-ready records 
• Ensure transparency 

Global Regulatory Perspective

While the U.S. remains restrictive, other regions have:

• More defined CBD frameworks 
• Conditional approvals 
• Emerging regulatory models 

Strategic Insight

Companies operating globally must:

Adapt to region-specific CBD regulations while preparing for U.S. changes

Maven Regulatory Solutions: Your CBD Compliance Partner

Maven Regulatory Solutions provides expert support in navigating complex CBD regulations.

Our Services

Regulatory Strategy Development

• U.S. and global CBD compliance planning 

Safety & Toxicology Support

• Data gap analysis 
• Risk assessments 

Labeling Compliance

• Claims review 
• Regulatory alignment 

Submission Strategy

• FDA engagement preparation 
• Future pathway readiness 

Planning to launch CBD products in the U.S.?

• Navigate FDA regulatory restrictions
• Build science-based compliance strategies
• Prepare for future CBD regulatory pathways
• Reduce legal and regulatory risks

Partner with Maven Regulatory Solutions today

Conclusion: A Science-Driven Path Forward

The U.S. Food and Drug Administration has made one point clear:

CBD regulation will be driven by science, safety, and evidence not market demand alone

While current restrictions remain in place, the evolving collaboration between FDA and Congress signals a transformational shift in CBD regulation.

For companies, this represents a critical opportunity to:

• Invest in safety research 
• Strengthening regulatory strategies 
• Prepare for future compliance frameworks 

Organizations that act proactively today will be best positioned to succeed in the next phase of the CBD market evolution.

Frequently Asked Questions

1. Is CBD legal in the U.S.?
It is legal in certain forms but restricted in foods and supplements.

2. Why is CBD restricted by FDA?
Because it is an active drug ingredient under the FD&C Act.

3. What is Epidiolex?
An FDA-approved CBD-based prescription drug.

4. Can CBD be added to food?
No, not under current regulations.

5. Will regulations change?
Yes, FDA is working with Congress on a new framework.

6. Are CBD products regulated?
Yes, especially regarding safety and labeling.

7. What are the main risks?
Liver toxicity, reproductive effects, and unknown long-term impacts.

8. How can companies prepare?
Through safety studies, compliance strategies, and regulatory monitoring.